Vol. 17/No. 19 | OncologyLive

Outfitted for Cancer Care

November 04, 2016

Technology is in the works that would allow medically useful personal health metrics to be collected by sensors that can be incorporated into clothing, accessories, or skin patches, and then transmitted electronically for analysi

Counting to 125: The Painstaking Journey to a Landmark Ovarian Cancer Biomarker

October 11, 2016

Robert C. Bast Jr, MD, who led the development of the first clinically relevant blood-based biomarker for ovarian cancer, was honored in the Gynecologic Malignancies category with a 2015 Giants of Cancer Care® award, a program that OncLive launched to recognize leaders in the field.

Society for Immunotherapy of Cancer: Leading the Way

October 04, 2016

OncLive is pleased to announce that the Society for Immunotherapy of Cancer (SITC) has joined the OncLive Strategic Alliance Partnership program, a collaborative effort to bring up-to-date clinical information to practicing oncology specialists.

Patient Preference Among Key Considerations in Frontline RCC Therapy

October 03, 2016

Historically, patients with advanced renal cell carcinoma have had few treatment options, but several targeted agents and one immunotherapy, the checkpoint inhibitor nivolumab, have been approved within the past 5 years, considerably expanding the RCC treatment arsenal. In the frontline setting, targeted agents are often the go-to therapy.

Wearable Therapy Making Inroads in Oncology

September 30, 2016

Two headgear items, a system of applying electromagnetic currents to patients with glioblastoma and a cooling cap for individuals undergoing chemotherapy for breast cancer, are early entries in the field.

SPINET Trial Could Alter Practice for Patients With Lung NETs

September 30, 2016

The SPINET trial is an international, phase III, randomized, double-blind study evaluating the efficacy and safety of lanreotide (Somatuline Depot) plus best supportive care compared with placebo plus best supportive care in patients with well-differentiated, metastatic and/or unresectable, typical or atypical lung neuroendocrine tumors.

Stereotactic Radiation Potential Emerges in Prostate Cancer

September 28, 2016

Stereotactic ablative radiosurgery, which is administered in far fewer but larger doses than conventional radiotherapy, has the potential to benefit a substantial proportion of patients with low-, intermediate-, and potentially even high-risk prostate cancers.

Prognostic Truths May Be in the Eye of the Beholder

September 28, 2016

Perhaps oncologists know that having a detailed understanding of population-based survival statistics is very different from such knowledge of the future clinical course of an individual patient.